OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Neurodegeneration is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	258
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	211
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	145
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	143
Tauopathies: new perspectives and challenges	142
Neuropathology and molecular diagnosis of Synucleinopathies	142
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	135
TDP-43 Pathology in Alzheimer’s Disease	132
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	126
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	126
Solving neurodegeneration: common mechanisms and strategies for new treatments	122
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	121
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	120
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	119
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	115
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	114
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	113
Cellular and pathological heterogeneity of primary tauopathies	112
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	106
New approaches to symptomatic treatments for Alzheimer’s disease	104
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	101
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	100
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	99
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	95
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	90

The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	82
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	72
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	70
The role of inflammasomes in vascular cognitive impairment	70
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	69
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	68
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	67
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	62
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	61
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	61
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes	60
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	59
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	58
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target	57
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	57
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	56
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	55
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	55
The informed road map to prevention of Alzheimer Disease: A call to arms	55
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	53
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	52
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	48
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease	48
Alzheimer’s disease – the journey of a healthy brain into organ failure	48